Literature DB >> 434251

Chlorimipramine therapy for obsessive-compulsive neurosis.

J Ananth, L Solyom, S Bryntwick, U Krishnappa.   

Abstract

Twenty patients with a history of treatment-resistant obsessional neurosis underwent a 4-week clinical trial of chlorimipramine. Scores on the Psychiatric Questionnaire for Obsessive Compulsive Neurosis, the Leyton Obsessional Inventory, and 3 self-assessments indicated that although there was no significant change in obsessive ruminations, obsessive rituals, horrific temptations, or pervading doubt, there was a substantial significant improvement in the obsessive symptom item and severity of obsessions, as well as anxiety, depression, and phobia. Side effects were mild. The authors believe that chlorimipramine is the most promising treatment for obsessive-compulsive neurosis.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 434251     DOI: 10.1176/ajp.136.5.700

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  5 in total

1.  Obsessive Compulsive Disorder: Improving prognosis through therapy and drug treatment.

Authors:  V Goli; R Krishnan; E Ellinwood
Journal:  Can Fam Physician       Date:  1991-06       Impact factor: 3.275

Review 2.  Clomipramine. An overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder.

Authors:  D McTavish; P Benfield
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

3.  Single photon emission computerized tomography in obsessive compulsive disorder: a preliminary study.

Authors:  B L Adams; L B Warneke; A J McEwan; B A Fraser
Journal:  J Psychiatry Neurosci       Date:  1993-05       Impact factor: 6.186

Review 4.  Current concepts in the pharmacological treatment of obsessive-compulsive disorder.

Authors:  J Zohar; R C Zohar-Kadouch; S Kindler
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

5.  Antidepressant-induced mania in obsessive compulsive disorder.

Authors:  Johann Philip; R Janaki
Journal:  Indian J Psychiatry       Date:  2012-04       Impact factor: 1.759

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.